中晚期肺癌的精准个体化治疗。熟练掌握肺癌的放化疗、分子靶向和生物治疗的最新国际诊疗规范。

自1995年起从事肿瘤内科专业，主要研究肺癌综合防治，擅长放疗、穿刺介入消融、放射性粒子植入和免疫靶向等治疗方式，并针对肺癌分期制定个体化治疗方案，争取达到最佳疗效。

代表性科研项目：（市科创委）长非编码RNA LAST1作为非小细胞肺癌的预后因子及其对肺癌发生发展的作用机制研究

代表性学术论文（参考文献格式）：

1. Zhang J, Tang S, Zhang C, Li M, Zheng Y, Hu X, Huang M, Cheng X.Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients. Front Oncol. 2022 Jan 11;11:742833.

2. Li Q, Zhou Q, Zhao S, Wu P, Shi P, Zeng J, Xiong X, Chen H, Kittaneh M, Bravaccini S, Zanoni M, Zhou C, Zhang J. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China. Transl Lung Cancer Res. 2022 Oct;11(10):2136-2147.

3. Chen C, Zhang C, Lin H, Liu Q, Wu L, Zhou C, Zhang J. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.Ther Adv Chronic Dis. 2022 Oct 17;13:20406223221125706.

4. Zhang J, Zhou N, Lin A, Luo P, Chen X, Deng H, Kang S, Guo L, Zhu W, Zhang J. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Cancer Immunol Immunother. 2021 Jan;70(1):137-151. doi: 10.1007/s00262-020-02668-8. Epub 2020 Jul 11. PMID: 32653938.

广东省胸部疾病学会遗传学专委会主任委员；广州抗癌协会肿瘤遗传专委会主任委员